Cartesian Therapeutics, Inc.
RNACCartesian Therapeutics is a late clinical-stage biotechnology company pioneering mRNA-engineered cell therapies for autoimmune diseases.
Table of contents
Earnings
Next report
Aug 6, 2026 (In 1 week)Competitors
By market cap
By revenue growth
Profile
Cartesian Therapeutics is a late clinical-stage biotechnology company pioneering mRNA-engineered cell therapies for autoimmune diseases. The company leverages its proprietary manufacturing platform to develop autologous CAR-T therapies that are designed for outpatient administration without the need for preconditioning chemotherapy. Its core value proposition centers on providing deep, durable clinical benefits and a precision immune reset while avoiding the genomic integration risks associated with conventional DNA-based cell therapies.
A pioneer in mRNA-based CAR-T therapies for autoimmune diseases, currently advancing a lead candidate through Phase 3 clinical trials with Orphan Drug and RMAT designations.
Questions, answered.
- What is Cartesian Therapeutics, Inc.'s market cap?
- Cartesian Therapeutics, Inc. (RNAC) has a market capitalization of $228.9M and trades on NASDAQ.
- Who are Cartesian Therapeutics, Inc.'s competitors?
- Cartesian Therapeutics, Inc.'s key competitors include Cabaletta Bio, Inc., Kyverna Therapeutics, Inc., Johnson & Johnson, and others. These companies compete in similar markets and product categories.
- Who does Cartesian Therapeutics, Inc. partner with?
- Cartesian Therapeutics, Inc.'s notable partners include Biogen MA, Inc., National Cancer Institute, Swedish Orphan Biovitrum AB.
- What subsidiaries does Cartesian Therapeutics, Inc. have?
- Cartesian Therapeutics, Inc.'s subsidiaries include Cartesian Bio, LLC.
- Where is Cartesian Therapeutics, Inc. headquartered?
- Cartesian Therapeutics, Inc. is headquartered in United States of America and employs approximately 38 people. It has been publicly traded since 2016.